Here's an idea, why not put your immense egos aside and offer $75/Share for GENZ. You know its still a bargain at that price - and may get the deal done. IMHO
Let's see, GENZ was selling for $50 in early July and all of the sudden a company with manufacturing problems and increasing competition to its marquee drugs is worth $75.Who are you trying to fool? Genzyme isn't worth a dollar over 55, and that might be too generous.
Really? Well I guess the market pricing GENZ at $73 today makes SNY bid at 69 more likely? What a bunch of Bozos. Copaxone sales are worth 1.6 Billion alone. Bozos ....
Patents are premier for a company that has so many drugs about to become generics. SNY should forgo the waste-of-time-low-balling and make a realistic offer.